Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-1197
U.S. Topical Pain Relief Market is poised to value USD 3622 million by 2028 end at a CAGR of 3.7% during the forecast period 2022 to 2028. An application of topical pain relief medications is made directly to the epidermal layer of the skin at the site of inflammation or pain. Topical pain relief products are designed to relieve pain and employ skin as a vehicle for the administration of drugs and exert major effects at the target site & in the central nervous system. Formulations like these contain analgesic or anesthetic agents that are applied to or around the painful area. A slow and gradual release of pain relief medication into the bloodstream is achieved by keeping the blood level relatively constant over time. It is less likely that these medications will cause side effects than oral medications. It is possible to administer both non-opioids and opioids as topical pain relievers. A non-opioid drug includes a nonsteroidal anti-inflammatory drug (NSAIDS), methyl salicylates, capsaicin, lidocaine, etc. Drugs that are considered opioids include buprenorphine and fentanyl. U.S. topical pain relief market growth is primarily driven by osteoarthritis and other bone-related conditions, including diabetic neuropathy, causing pain. U.S. topical pain relief market growth is also boosted by the adoption of topical pain relief products, which cause fewer side effects than oral pain relief, and an increase in the number of geriatrics across the country. Nevertheless, topical pain relievers can cause skin irritation and have a strong smell that hampers market growth. A lucrative growth opportunity for the market is expected to be offered by the development of the online platform for topical therapeutics. Topical pain relievers are a good alternative for those unable to take oral medications. Topical pain relievers include the drug administrations of capsaicin, tricyclic antidepressants, ketamine, opioids, clonidine, NSAIDs, local anaesthetics and cannabinoids. These medications are available in the form of foams, roll-ons. creams, gels, sprays, patches and sticks. Basis the distribution channel, the U.S topical pain relief market is fragmented into e-commerce, pharmacies and drug stores and retail and grocery stores. Pharmacies and drug stores accounted for the largest U.S topical pain relief market share due to wide availability and higher presence of drugs. On the contrary, the e-commerce segment is predicted to exhibit significant U.S. topical pain relief market growth over the forecast period due to higher literacy digital-wise amongst the population. Furthermore, these pharmacies offer many advantages like more convenience, easy access to patient reviews, fewer expenses and price comparisons, which drive the segment’s market growth. The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A. U.S Topical Pain Relief Market Segmentation: By Therapeutic Class • Non-opioids o Non-steroidal Anti-Inflammatory Drugs (NSAIDS) o Methyl Salicylate o Capsaicin o Lidocaine o Other Non-opioids • Opioids o Buprenorphine o Fentanyl By Type • Prescription Pain Relief • Over-the-counter (OTC) Pain Relief By Formulation • Cream • Gel • Spray • Patch • Others By Distribution Channel • Pharmacies & Drug Stores • E-commerce • Retail & Grocery Stores FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the High Performance Medical Plastics Market By Therapeutic Class, By Type, By Formulation and By Distribution Channel To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions— U.S. To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
An application of topical pain relief medications is made directly to the epidermal layer of the skin at the site of inflammation or pain. Topical pain relief products are designed to relieve pain and employ skin as a vehicle for the administration of drugs and exert major effects at the target site & in the central nervous system. Formulations like these contain analgesic or anesthetic agents that are applied to or around the painful area. A slow and gradual release of pain relief medication into the bloodstream is achieved by keeping the blood level relatively constant over time. It is less likely that these medications will cause side effects than oral medications. It is possible to administer both non-opioids and opioids as topical pain relievers. A non-opioid drug includes a nonsteroidal anti-inflammatory drug (NSAIDS), methyl salicylates, capsaicin, lidocaine, etc. Drugs that are considered opioids include buprenorphine and fentanyl. U.S. topical pain relief market growth is primarily driven by osteoarthritis and other bone-related conditions, including diabetic neuropathy, causing pain. U.S. topical pain relief market growth is also boosted by the adoption of topical pain relief products, which cause fewer side effects than oral pain relief, and an increase in the number of geriatrics across the country. Nevertheless, topical pain relievers can cause skin irritation and have a strong smell that hampers market growth. A lucrative growth opportunity for the market is expected to be offered by the development of the online platform for topical therapeutics.
Topical pain relievers are a good alternative for those unable to take oral medications. Topical pain relievers include the drug administrations of capsaicin, tricyclic antidepressants, ketamine, opioids, clonidine, NSAIDs, local anaesthetics and cannabinoids. These medications are available in the form of foams, roll-ons. creams, gels, sprays, patches and sticks.
Basis the distribution channel, the U.S topical pain relief market is fragmented into e-commerce, pharmacies and drug stores and retail and grocery stores. Pharmacies and drug stores accounted for the largest U.S topical pain relief market share due to wide availability and higher presence of drugs. On the contrary, the e-commerce segment is predicted to exhibit significant U.S. topical pain relief market growth over the forecast period due to higher literacy digital-wise amongst the population. Furthermore, these pharmacies offer many advantages like more convenience, easy access to patient reviews, fewer expenses and price comparisons, which drive the segment’s market growth.
The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A.
U.S Topical Pain Relief Market Segmentation:
By Therapeutic Class • Non-opioids o Non-steroidal Anti-Inflammatory Drugs (NSAIDS) o Methyl Salicylate o Capsaicin o Lidocaine o Other Non-opioids • Opioids o Buprenorphine o Fentanyl By Type • Prescription Pain Relief • Over-the-counter (OTC) Pain Relief By Formulation • Cream • Gel • Spray • Patch • Others By Distribution Channel • Pharmacies & Drug Stores • E-commerce • Retail & Grocery Stores
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. U.S. Topical Pain Relief Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of U.S. Topical Pain Relief Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. U.S. Topical Pain Relief Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. U.S. Topical Pain Relief Market, By Therapeutic Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Non-opioids 7.1.1. Non-steroidal Anti-Inflammatory Drugs (NSAIDS) 7.1.2.Methyl salicylate 7.1.3. Capsaicin 7.1.4. Lidocaine 7.1.5. Other Non-opioids 7.2. Opioids 7.2.1. Buprenorphine 7.2.2. Fentanyl 8. U.S. Topical Pain Relief Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Prescription Pain Relief 8.2. Over-the-counter (OTC) Pain Relief 9. U.S. Topical Pain Relief Market, By Formulation Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Cream 9.2. Gel 9.3. Spray 9.4. Patch 9.5. Others 10. U.S. Topical Pain Relief Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmacies & Drug Stores 10.2. E-commerce 10.3. Retail & Grocery Stores 11. Market Share Analysis and Competitive Landscape 11.1. U.S. Landscape - Key Players, Revenue and Presence 11.2. U.S. Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 11.3. U.S. Emerging Companies 11.4. U.S. - Market Share Analysis and Key Regional Players 11.5. U.S. Key Player - Growth Matrix 12. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 12.1. Johnson & Johnson 12.1.1. Company Overview 12.1.2. Product Portfolio 12.1.3. SWOT Analysis 12.1.4. Financial Overview 12.1.5. Strategic Overview 12.2. Novartis AG. 12.2.1. Company Overview 12.2.2. Product Portfolio 12.2.3. SWOT Analysis 12.2.4. Financial Overview 12.2.5. Strategic Overview 12.3. GlaxoSmithKline Plc. 12.3.1. Company Overview 12.3.2. Product Portfolio 12.3.3. SWOT Analysis 12.3.4. Financial Overview 12.3.5. Strategic Overview 12.4. Pfizer Inc. 12.4.1. Company Overview 12.4.2. Product Portfolio 12.4.3. SWOT Analysis 12.4.4. Financial Overview 12.4.5. Strategic Overview 12.5 Reckitt Benckiser Group Plc. 12.5.1. Company Overview 12.5.2. Product Portfolio 12.5.3. SWOT Analysis 12.5.4. Financial Overview 12.5.5. Strategic Overview 12.6 Sanofi S.A. 12.6.1. Company Overview 12.6.2. Product Portfolio 12.6.3. SWOT Analysis 12.6.4. Financial Overview 12.6.5. Strategic Overview 12.7. Topical BioMedics, Inc. 12.7.1. Company Overview 12.7.2. Product Portfolio 12.7.3. SWOT Analysis 12.7.4. Financial Overview 12.7.5. Strategic Overview 12.8. AdvaCare Pharma 12.8.1. Company Overview 12.8.2. Product Portfolio 12.8.3. SWOT Analysis 12.8.4. Financial Overview 12.8.5. Strategic Overview 12.9. Sun Pharmaceutical Industries Ltd. 12.9.1. Company Overview 12.9.2. Product Portfolio 12.9.3. SWOT Analysis 12.9.4. Financial Overview 12.9.5. Strategic Overview 12.10. Nestle S.A. 12.10.1. Company Overview 12.10.2. Product Portfolio 12.10.3. SWOT Analysis 12.10.4. Financial Overview 12.10.5. Strategic Overview 13. Pre and Post COVID-19 Impact 13.1. Positive influence on the healthcare industry 13.2. The financial disruption of the manufacturing sector 13.3. Impact of COVID-19 on emerging companies 13.4. Significant mandates in the healthcare regulations initiated by administrations 13.5. The overall economic slowdown of the developing and developed nations 14. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. U.S. Topical Pain Relief Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of U.S. Topical Pain Relief Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. U.S. Topical Pain Relief Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. U.S. Topical Pain Relief Market, By Therapeutic Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Non-opioids 7.1.1. Non-steroidal Anti-Inflammatory Drugs (NSAIDS) 7.1.2.Methyl salicylate 7.1.3. Capsaicin 7.1.4. Lidocaine 7.1.5. Other Non-opioids 7.2. Opioids 7.2.1. Buprenorphine 7.2.2. Fentanyl
8. U.S. Topical Pain Relief Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Prescription Pain Relief 8.2. Over-the-counter (OTC) Pain Relief
9. U.S. Topical Pain Relief Market, By Formulation Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Cream 9.2. Gel 9.3. Spray 9.4. Patch 9.5. Others
10. U.S. Topical Pain Relief Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmacies & Drug Stores 10.2. E-commerce 10.3. Retail & Grocery Stores
11. Market Share Analysis and Competitive Landscape 11.1. U.S. Landscape - Key Players, Revenue and Presence 11.2. U.S. Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 11.3. U.S. Emerging Companies 11.4. U.S. - Market Share Analysis and Key Regional Players 11.5. U.S. Key Player - Growth Matrix
12. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 12.1. Johnson & Johnson 12.1.1. Company Overview 12.1.2. Product Portfolio 12.1.3. SWOT Analysis 12.1.4. Financial Overview 12.1.5. Strategic Overview 12.2. Novartis AG. 12.2.1. Company Overview 12.2.2. Product Portfolio 12.2.3. SWOT Analysis 12.2.4. Financial Overview 12.2.5. Strategic Overview 12.3. GlaxoSmithKline Plc. 12.3.1. Company Overview 12.3.2. Product Portfolio 12.3.3. SWOT Analysis 12.3.4. Financial Overview 12.3.5. Strategic Overview 12.4. Pfizer Inc. 12.4.1. Company Overview 12.4.2. Product Portfolio 12.4.3. SWOT Analysis 12.4.4. Financial Overview 12.4.5. Strategic Overview 12.5 Reckitt Benckiser Group Plc. 12.5.1. Company Overview 12.5.2. Product Portfolio 12.5.3. SWOT Analysis 12.5.4. Financial Overview 12.5.5. Strategic Overview 12.6 Sanofi S.A. 12.6.1. Company Overview 12.6.2. Product Portfolio 12.6.3. SWOT Analysis 12.6.4. Financial Overview 12.6.5. Strategic Overview 12.7. Topical BioMedics, Inc. 12.7.1. Company Overview 12.7.2. Product Portfolio 12.7.3. SWOT Analysis 12.7.4. Financial Overview 12.7.5. Strategic Overview 12.8. AdvaCare Pharma 12.8.1. Company Overview 12.8.2. Product Portfolio 12.8.3. SWOT Analysis 12.8.4. Financial Overview 12.8.5. Strategic Overview 12.9. Sun Pharmaceutical Industries Ltd. 12.9.1. Company Overview 12.9.2. Product Portfolio 12.9.3. SWOT Analysis 12.9.4. Financial Overview 12.9.5. Strategic Overview 12.10. Nestle S.A. 12.10.1. Company Overview 12.10.2. Product Portfolio 12.10.3. SWOT Analysis 12.10.4. Financial Overview 12.10.5. Strategic Overview
13. Pre and Post COVID-19 Impact 13.1. Positive influence on the healthcare industry 13.2. The financial disruption of the manufacturing sector 13.3. Impact of COVID-19 on emerging companies 13.4. Significant mandates in the healthcare regulations initiated by administrations 13.5. The overall economic slowdown of the developing and developed nations
14. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics